Arrowsmith is a drug discovery startup developing “phage therapy,” an innovative treatment for drug-resistant bacterial infections and difficult-to-treat bacterial infections, using bacteriophages, which are viruses that prey on bacteria.
Company name
Arrowsmith Inc.
Type of business
Medical(medical devices, drug discovery)
Representatives
Hiroki Ando
Establishing a company
February 2025
Investment announcement date
August 2025
Capitalist
Jun Hayashi
HP
https://arrowsmith.co.jp/Phasing
Early
